Key result
Cystatin-C-based eGFR inversely correlates with atherogenic TC/HDL ratio, unlike creatinine-based eGFR.
Why the study?
Chronic kidney disease is frequently complicated by the coexistence of cardiovascular events, making it essential to identify cardiovascular risk in chronic kidney disease.
Does eGFR estimated by cystatin-C correlate better with atherogenic lipid profiles than eGFR estimated by creatinine in patients with chronic kidney disease?
Cross-Sectional (n=120)
No
Does eGFR estimated by cystatin-C correlate better with atherogenic lipid profiles than eGFR estimated by creatinine in patients with chronic kidney disease?
Estimated GFR calculated by cystatin-C correlates significantly better with atherogenic lipid profiles than creatinine-based eGFR in CKD patients, suggesting it may be a superior marker for cardiovascular risk stratification.
Answers are grounded in this paper and cite their sources.
Cystatin-C eGFR may aid CV risk assessment in CKD; leaves open whether it improves stratification over creatinine-based estimates.
Chronic kidney disease (CKD) is frequently complicated by the coexistence of cardiovascular (CV) events, making it essential to identify CV risk in CKD. Serum cystatin-C is an upcoming renal biomarker, which is used to measure estimated glomerular filtration rate (eGFR) by the CKD-EPI formula.
No takes yet. Share an insight, caveat, or question.
Ravi et al. (2020) conducted a cross-sectional in Chronic Kidney Disease (n=120). eGFR by cystatin-C (CKD-EPI) vs. eGFR by creatinine (MDRD) was evaluated on Correlation between eGFR and TC/HDL ratio (r = -0.26, p=0.004). Estimated GFR using serum cystatin-C correlated inversely and significantly with the atherogenic TC/HDL ratio (r = -0.26, p = 0.004), whereas eGFR using serum creatinine did not.
Synapse has enriched 10 related papers. Consider them for comparative context: